Knight Therapeutics reports Q1 EPS C$0.02 vs. (C$0.04) last year

Reports Q1 revenue C$88.07M vs. C$86.6M. “I am pleased to announce that for the three months ended March 31, 2025, we reported adjusted revenues of $88 million, a growth of 3% over the same period in prior year, with our promoted brands growing at 9% and an adjusted EBITDA1 over $12 million. In addition, we have expanded an existing partnership with the addition of Onicit and have advanced our pipeline with the submission of Tavalisse in Argentina and the regulatory approval of Pemazyre in Mexico. We continued our progress on the commercial font with the launch of Minjuvi in Mexico and re-launch of Onicit in Mexico and Brazil. In addition, we have announced the acquisition of Paladin. This transaction will add a profitable portfolio, critical mass and significantly increases the size of our business in Canada while bringing a stable source of cash flow that will help fund our growth in Canada and Latin American,” said Samira Sakhia, President and Chief Executive Officer of Knight Therapeutics (KHTRF) Inc.